|
|
ix | |
Preface |
|
xiii | |
Acknowledgments |
|
xv | |
|
Part One Fundamentals of cardiovascular stents |
|
|
1 | (134) |
|
1 Overview of cardiovascular stent designs |
|
|
3 | (24) |
|
|
|
3 | (1) |
|
1.2 Percutaneous coronary interventions |
|
|
4 | (1) |
|
|
4 | (4) |
|
|
8 | (9) |
|
|
17 | (1) |
|
1.6 Summary of current state of the art and future perspective |
|
|
18 | (9) |
|
|
19 | (7) |
|
|
26 | (1) |
|
2 Fundamentals of bare-metal stents |
|
|
27 | (18) |
|
|
|
2.1 Clinical study of bare-metal stents |
|
|
27 | (1) |
|
2.2 Complimentary manufacturing of bare-metal stents |
|
|
28 | (2) |
|
2.3 Validation of mechanical properties of metals for bare-metal stent |
|
|
30 | (1) |
|
|
31 | (7) |
|
2.5 Finite element analysis of stents |
|
|
38 | (4) |
|
|
42 | (3) |
|
|
43 | (2) |
|
3 Development of drug-eluting stents (DES) |
|
|
45 | (12) |
|
|
|
|
|
|
3.1 First coronary intervention and development of stents |
|
|
45 | (1) |
|
3.2 Pathophysiology of restenosis |
|
|
46 | (1) |
|
3.3 Methods of testing stent performance and their limitations |
|
|
46 | (1) |
|
3.4 First-generation drug-eluting stents |
|
|
47 | (1) |
|
3.5 Second-generation DES |
|
|
48 | (2) |
|
|
50 | (4) |
|
|
54 | (3) |
|
|
54 | (3) |
|
4 Polymer-free drug-eluting stents |
|
|
57 | (18) |
|
|
|
57 | (1) |
|
4.2 Moving beyond polymer controlled stent drug release |
|
|
57 | (1) |
|
4.3 Direct coating of drug |
|
|
58 | (2) |
|
4.4 Stent platform modifications |
|
|
60 | (6) |
|
4.5 Role of stent surface in vessel healing |
|
|
66 | (1) |
|
4.6 Summary and future perspectives |
|
|
67 | (8) |
|
|
68 | (6) |
|
|
74 | (1) |
|
5 Fundamentals of bioresorbable stents |
|
|
75 | (24) |
|
|
|
|
|
|
|
|
|
75 | (4) |
|
5.2 Current bioresorbable stents technology |
|
|
79 | (13) |
|
|
92 | (7) |
|
|
93 | (4) |
|
|
97 | (2) |
|
6 Bioabsorbable metallic stents |
|
|
99 | (36) |
|
|
|
99 | (1) |
|
6.2 General design criterions of bioabsorbable metallic stents |
|
|
100 | (2) |
|
6.3 Development of Mg-based bioabsorbable metallic stents |
|
|
102 | (11) |
|
6.4 Development of Fe-based bioabsorbable metallic stents |
|
|
113 | (9) |
|
6.5 Development of Zn-based bioabsorbable metallic stents |
|
|
122 | (6) |
|
6.6 Challenges and opportunities for bioabsorbable metallic stents |
|
|
128 | (7) |
|
|
129 | (6) |
|
Part Two Coatings and surface modification of cardiovascular stents |
|
|
135 | (94) |
|
7 Physico-chemical stent surface modifications |
|
|
137 | (12) |
|
|
|
|
|
|
|
|
137 | (1) |
|
7.2 Stent surface functionalization |
|
|
138 | (3) |
|
7.3 Thiol groups functionalized surface |
|
|
141 | (3) |
|
|
144 | (5) |
|
|
144 | (5) |
|
8 Chemical vapor deposition of cardiac stents |
|
|
149 | (6) |
|
|
|
149 | (1) |
|
8.2 Chemical vapor deposition |
|
|
150 | (1) |
|
8.3 CVD passivation process evaluation |
|
|
151 | (1) |
|
|
152 | (1) |
|
|
152 | (3) |
|
|
152 | (2) |
|
|
154 | (1) |
|
9 Polymer coatings for biocompatibility and reduced nonspecific adsorption |
|
|
155 | (44) |
|
|
|
|
|
|
|
|
|
|
|
|
156 | (2) |
|
9.2 Classification of plasma |
|
|
158 | (9) |
|
9.3 Added value of nonthermal plasma for stent applications: Polymer coatings |
|
|
167 | (20) |
|
|
187 | (12) |
|
|
188 | (1) |
|
|
188 | (11) |
|
10 Coating stability for stents |
|
|
199 | (12) |
|
|
|
|
|
199 | (3) |
|
|
202 | (2) |
|
|
204 | (1) |
|
10.4 DES and biodegradable polymers |
|
|
205 | (1) |
|
10.5 Stability tests involving endothelial cells |
|
|
206 | (1) |
|
10.6 Conclusions and perspectives |
|
|
207 | (4) |
|
|
207 | (4) |
|
11 Simple one-step covalent immobilization of bioactive agents without use of chemicals on plasma-activated low thrombogenic stent coatings |
|
|
211 | (18) |
|
|
|
|
|
|
|
|
|
|
|
11.1 Functionalization of stents to improve their clinical performance |
|
|
211 | (2) |
|
11.2 Bioengineering of plasma-activated coatings for stents |
|
|
213 | (7) |
|
11.3 Biological properties of PAC coated stents |
|
|
220 | (9) |
|
|
226 | (3) |
|
Part Three Biofunctionalisation of cardiovascular stent surfaces |
|
|
229 | (104) |
|
12 Chemistry of targeted immobilization of biomediators |
|
|
231 | (20) |
|
|
|
231 | (3) |
|
12.2 Targeted immobilization chemistries |
|
|
234 | (8) |
|
|
242 | (9) |
|
|
242 | (9) |
|
13 Functionalized cardiovascular stents: Cardiovascular stents incorporated with stem cells |
|
|
251 | (40) |
|
|
|
|
251 | (1) |
|
13.2 Adventitial biology for coronary artery disease (CAD) |
|
|
252 | (1) |
|
13.3 Role of stem/progenitor cells in atherosclerosis |
|
|
253 | (5) |
|
13.4 Current treatment strategies against atherosclerosis |
|
|
258 | (4) |
|
13.5 Preparation and surface modification of nanofiber |
|
|
262 | (7) |
|
13.6 Functionalized cardiovascular stents for treatment of atherosclerosis |
|
|
269 | (6) |
|
|
275 | (16) |
|
|
276 | (15) |
|
14 Nitric oxide donor delivery |
|
|
291 | (14) |
|
|
|
|
291 | (1) |
|
|
292 | (1) |
|
14.3 Nitric oxide and vascular function |
|
|
293 | (1) |
|
14.4 Localized NO delivery |
|
|
294 | (1) |
|
14.5 Nitric oxide donor stents (the evidence) |
|
|
295 | (1) |
|
|
296 | (1) |
|
|
297 | (8) |
|
|
297 | (8) |
|
15 Immobilization of peptides on cardiovascular stent |
|
|
305 | (14) |
|
|
|
|
15.1 Introduction: Cardiovascular materials and biocompatibility |
|
|
305 | (2) |
|
15.2 Metals and alloys for endovascular stent |
|
|
307 | (1) |
|
15.3 Immobilization of peptides: The grafting technique |
|
|
308 | (3) |
|
15.4 Guiding the tissue regeneration: Surface modification of cardiovascular stents |
|
|
311 | (2) |
|
15.5 Future trends/conclusion |
|
|
313 | (6) |
|
|
313 | (5) |
|
|
318 | (1) |
|
16 Immobilization of antibodies on cardiovascular stents |
|
|
319 | (14) |
|
|
|
|
319 | (1) |
|
16.2 The use of antibodies in stent functionalization |
|
|
320 | (5) |
|
16.3 Protein-stent linking approaches |
|
|
325 | (3) |
|
16.4 Applications of stent-immobilized antibodies |
|
|
328 | (4) |
|
|
332 | (1) |
Acknowledgments |
|
333 | (1) |
References |
|
333 | (10) |
Index |
|
343 | |